Another example of a successful cancer drug is Imatinib (Glivec) which targets BCR–ABL and platelet-derived growth factor receptor PDGFR tyrosine kinases which are driving hematopoietic malignancies and gastrointestinal stromal tumors [203]. This evidence concerns the gene BCR and cancer.